Gene sequencing refers to the process of determining the nucleotide sequence of deoxyribonucleic acid (DNA) by sequencing equipment to interpret the genetic code of DNA and provide guidance for life science research, clinical diagnosis and treatment. A gene is a functional fragment on a DNA molecule. It is the basic unit of genetic information and the most basic factor that determines all biological species. The gene determines the life and death of a person. It is the cause of health, beauty, and longevity. It is the manipulator and regulator of life. .
With the continuous development of the economy and the standardization of the sequencing market, the growth rate of China's sequencing market is obvious. China will enter a period of rapid development and is expected to become one of the bases of the global NGS market. The compound annual growth rate is expected to be 20-25% in 2012-2017. , ranking in the forefront of the world.
Huada Gene is currently the largest gene sequencing center in China, accounting for about 20-30% of the market. In 2014, 2015 and 2016, Huada Gene achieved operating income of 1.132 billion yuan, 1.319 billion yuan and 1.711 billion yuan respectively. Based on the revenue of Huada Gene, the market share is about 20-30%. According to the data of the Prospective Industry Research Institute's “Generation and Market Strategy Report of Gene Sequencing Industryâ€, the scale of China's sequencing market is about 5.3 billion yuan in 2016. It is expected to exceed 15 billion yuan in 2022.
Forecast of China's Gene Sequencing Market Size in 2017-2022
According to industry insiders, from the global perspective, the fastest growing size of the genetic sequencing market is the Asian market. China's demographic dividend brings huge market space for the development of genetic sequencing and promotes the rapid development of the industry. Up to now, China's gene sequencing industry has experienced four stages: no supervision, stop, pilot application, and cancellation of declaration.
In fact, as early as 2017, China issued the “13th Five-Year Plan for Biological Industry Developmentâ€. In addition, Huada Gene, a leading company in the gene sequencing industry, successfully landed in A-shares, and the third-generation genetic sequencer independently developed by China was approved for production. The policy continued to increase, the capital was actively assisted, and the technology accelerated innovation, marking the healthy development of China's gene sequencing industry. High speed track.
At present, China has more than 200 high-throughput gene sequencing services companies, mainly in the fields of disease prevention and early screening, assisted disease diagnosis, accompanying diagnosis and big data services. Among them, the concentration of the sequencing service industry is relatively high, and leading enterprises such as Huada Gene, Berry and Kang occupy the majority of the market share, and the market structure is relatively stable. As the number of industry participants increases, policy regulation becomes stricter, and profit margins decline, small-scale sequencing service companies will gradually be eliminated by the market.
In recent years, the policy has led the country's genetic sequencing industry to be on the right track. Upstream genetic sequencer technology barriers are constantly trying to break through, sequencing consumables are expected to become the upstream breakthrough; midstream gene sequencing services are relatively mature, market concentration is high, the pattern is stable; tumor diagnosis and treatment is expected to become the next explosion point; middle and lower reaches Internet technology Integration into a development trend, the database will become the core competitiveness of genetic sequencing services enterprises; the uncertainty of breakthroughs in gene sequencing technology makes the genetic sequencing industry have certain investment risks.
However, in the eyes of industry experts, for the entire genetic industry, it is still in its infancy, and the commercialization of the genetic testing industry is only the tip of the iceberg. Future gene sequencing still has great commercial potential and development value. With the fields of diagnosis, personalized treatment, and drug synthesis, there are huge development prospects. However, due to the fact that basic research, engineering technology, and policies are not yet mature, it will take some time to realize commercial application.
Laboratory Diagnostic,Reagent Strips For Urinalysis,Assay Kits,LETIA Assay Kit,Urinalysis Assay Kits
Jilin Sinoscience Technology Co. LTD , https://www.jlgkscience.com